Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare bill heads to White House

Executive Summary

President Bush's plan to veto legislation, H.R. 6331, intended to stave off cuts in Medicare physician rates is motivated primarily by provisions to make up for those cuts with reductions in payments to Medicare Advantage plans, White House officials indicated during a July 10 press briefing. Still intact in H.R. 6331 are a number of provisions in the drug area, including Medicare payment incentives for physicians to use electronic prescribing; bundled payments for dialysis-related services, including drugs; Medicare coverage of benzodiazepines; permanence of Medicare Part D coverage of all or substantially all drugs in six classes, and suspension of Medicaid average manufacturer price rules. The Senate passed the measure July 9 by what, if it holds, is a veto-proof 69-30 margin. It is identical to the version that passed the House 355-59 on June 24 (1"The Pink Sheet," June 30, 2008, p. 23)

You may also be interested in...



Medicare Bill Strikes Out Again In Senate After Home Run In House

Momentum from a surprising House passage of a slightly modified version of the Sen. Max Baucus-penned Medicare physician payment legislation was not quite enough to carry the bill on a second try in the Senate on June 26

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel